Offline Website CreatorOn December 6, Professor Yin Xiushan's team from RocRock Bio and the team of Directors Liu Qiaofei and Liao Quan and Academician Zhao Yupeng from the Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences jointly published a research paper in the journal Molecular Cancer....
CAR-M cells, characterized by their superior capacity for immune infiltration and effective targeted killing, have demonstrated significant clinical potential in the treatment of solid tumors...
RocRock Bio, at the special invitation of STAR Protocol in the CELL Press series, recently published an article titled Protocol for generating of human CAR-engineered macrophages by Vpx-containing lentivirus...
Based on the forecast from "The Lancet Commission on prostate cancer: planning for the surge in cases"...
On August 5, 2024, journalists from Suzhou Broadcasting and Television Station visited Kunshi Bio in BioBAY, Suzhou Industrial Park, and had an in - depth interview with Dr. Yin Xiushan, the founder. They also visited the company's labs during the interview...
Recently, as the Provincial Department of Science and Technology announced the "List of Jiangsu Province's First Batch of Technology - based SMEs Proposed for Inclusion in 2024" and Suzhou Municipal Bureau of Science and Technology announced the "List of Suzhou City's Proposed Recognition of Innovative SMEs for 2024", ...
In July 2024, RocRock Bio and Shandong First Medical University visited Armenia, a Belt and Road country, to exchange views on the prevention and treatment of Mediterranean fever and reached a cooperation intention on rare disease projects....
During the signing ceremony, RocRock Bio and Porton Bio formed a strategic partnership to jointly advance the IND application of the RR-M01 clinical pipeline. The event was attended by Dr. Yin Xiushan, founder of RocRock Bio, and Tao Rong, CEO of Porton Bio. On March 19, 2024, RocRock Bio...
In February 2024, RocRock Bio, dedicated to developing macrophage - based therapies for solid tumors, completed a Pre - A financing round, raising tens of millions of yuan. This funding was led by Guozhu Capital, a company under Ronghui Group, with continued investment from Deshui Capital...
RocRock Bio has recently completed the first - dose administration of its third-generation CAR-M drug, RR-M01 injection, in a clinical trial participant at Xuzhou Medical University Affiliated Hospital, bringing to a close
Offline Website Creator